Tovetumab - CISMeF

Preferred Label : Tovetumab;

NCIt synonyms : Anti-Platelet-Derived Growth Factor Receptor Alpha Monoclonal Antibody MEDI-575;

NCIt related terms : Anti-PDGFR Alpha Monoclonal Antibody MEDI-575;

NCIt definition : A humanized monoclonal antibody directed against the platelet-derived growth factor receptor (PDGFR) alpha with potential antineoplastic activity. Tovetumab inhibits activation of the cell-surface tyrosine kinase PDGFR alpha subunit and subsequent triggering of mitogenic signaling pathways, including the JAK/STAT, PI3K/Akt, and MAP kinase pathways. PDGFR alpha acts as a mitogenic signaling receptor for cells of mesenchymal origin and inhibition of receptor activity may inhibit tumor cell proliferation.;

UNII : 2XY62K75UV;

CAS number : 1243266-04-7;

Molecule name : MEDI-575;

Détails

Origin ID

C82684;

UMLS CUI

C4519596;

Automatic exact mappings (from CISMeF team)
- Tovetumab [MeSH concept]
Currated CISMeF NLP mapping
- Tovetumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Tovetumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Platelet-Derived Growth Factor Receptor Alpha [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients